HHS Announced $700 Million for Addiction This Week. The Same Administration Cut Fentanyl Test Strips.

On June 17, HHS Secretary Kennedy announced more than $700 million in new behavioral health funding: $96 million for the STREETS program, which funds street-based engagement and recovery support; $238.6 million for the 988 Suicide and Crisis Lifeline; $80 million for substance use prevention, treatment, and recovery. SAMHSA separately announced $40 million in funding for addiction prevention and child trauma on June 11. On its face, this is a significant investment.

The same administration, in the same April-to-June window, banned federal funding for fentanyl test strips, zeroed out syringe service programs, and cut at least $345 million from harm reduction programs — simultaneously with a $700 million expansion announcement. These two things are not contradictory. They describe a framework.

The framework: the federal government will fund addiction treatment as a path to recovery. It will fund crisis response. It will fund mental health. It will not fund the tools and programs that help people who are actively using drugs remain alive while they are using, because those tools and programs are understood, within this framework, as facilitating drug use rather than stopping it.

This is a values choice, not a budgetary one. The programs being cut cost, in aggregate, less than the overhead of the programs being funded. Fentanyl test strips cost under two dollars each. Syringe exchanges cost between $17 and $71 per client per year in a review of cost-effectiveness studies, and prevent hospitalizations that cost tens of thousands of dollars each. The cuts are not about money.

They are about the answer to a question: what does the federal government owe to someone who is currently using drugs? The funding expansion answers: treatment access, crisis support, children’s welfare. The funding cuts answer: not the tools to use more safely.

This is a coherent framework. It is also one that public health research has consistently shown to be wrong on its own terms — harm reduction does not increase drug use, it increases survival and the eventual willingness to seek treatment. The evidence has been available for 30 years.

For providers, case managers, and organizations navigating both sides of this: the $700 million expansion includes funding categories relevant to SUD treatment, telehealth, and community-based behavioral health. The cuts are concentrated in specific harm reduction programs. Neither replaces the other. Track both, because your patients and clients will be affected by both, often at the same time.

The political accountability question is simpler: when overdose deaths rise — if the medetomidine trajectory and nitazene data push the overall number back up — someone will have made the decision that defunded the programs that were keeping the number going down. That decision was made in April. We are watching the timeline now.